丸美生物筹划发行H股股票并申请在香港联交所上市

Core Viewpoint - Mamei Biological (603983.SH) plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange to enhance its capital strength and overseas financing capabilities, aiming to improve its overall competitiveness and accelerate its international business strategy [1] Group 1 - The company aims to strengthen its capital and financing capabilities through the issuance of H-shares [1] - The listing on the Hong Kong Stock Exchange is part of the company's overall development strategy and operational needs [1] - The initiative is expected to enhance the company's comprehensive competitiveness [1]